130 related articles for article (PubMed ID: 15614736)
41. Metallothionein isoform II expression in hyperplastic, dysplastic and neoplastic prostatic lesions.
El Sharkawy SL; Abbas NF; Badawi MA; El Shaer MA
J Clin Pathol; 2006 Nov; 59(11):1171-4. PubMed ID: 16574721
[TBL] [Abstract][Full Text] [Related]
42. [Expression of nuclear Ki-67 antigen in prostatic high grade intraepithelial neoplasia and prostatic carcinoma].
Veliiković LJ; Dordević B; Rancić G; Marjanović G
Vojnosanit Pregl; 2007 May; 64(5):325-30. PubMed ID: 17585548
[TBL] [Abstract][Full Text] [Related]
43. Prolactin- and testosterone-induced carboxypeptidase-D correlates with increased nitrotyrosines and Ki67 in prostate cancer.
Thomas LN; Merrimen J; Bell DG; Rendon R; Too CK
Prostate; 2015 Nov; 75(15):1726-36. PubMed ID: 26202060
[TBL] [Abstract][Full Text] [Related]
44. Loss of low-affinity nerve growth factor receptor during malignant transformation of the human prostate.
Perez M; Regan T; Pflug B; Lynch J; Djakiew D
Prostate; 1997 Mar; 30(4):274-9. PubMed ID: 9111606
[TBL] [Abstract][Full Text] [Related]
45. Basal cell cocktail (34betaE12 + p63) improves the detection of prostate basal cells.
Zhou M; Shah R; Shen R; Rubin MA
Am J Surg Pathol; 2003 Mar; 27(3):365-71. PubMed ID: 12604893
[TBL] [Abstract][Full Text] [Related]
46. Loss of the cyclin-dependent kinase inhibitor p27(Kip1) protein in human prostate cancer correlates with tumor grade.
Guo Y; Sklar GN; Borkowski A; Kyprianou N
Clin Cancer Res; 1997 Dec; 3(12 Pt 1):2269-74. PubMed ID: 9815624
[TBL] [Abstract][Full Text] [Related]
47. Transforming growth factor beta 1 and androgen receptors in prostate neoplasia.
Cardillo MR; Petrangeli E; Salvatori L; Ravenna L; Di Silverio F
Anal Quant Cytol Histol; 2000 Oct; 22(5):403-10. PubMed ID: 11064817
[TBL] [Abstract][Full Text] [Related]
48. Lactoferrin in benign hypertrophy and carcinomas of the prostatic gland.
Barresi G; Tuccari G
Virchows Arch A Pathol Anat Histopathol; 1984; 403(1):59-66. PubMed ID: 6202054
[TBL] [Abstract][Full Text] [Related]
49. Ki-67 immunolabeling in pre-malignant lesions and carcinoma of the prostate. Histological correlation and prognostic evaluation.
Muñoz E; Gómez F; Paz JI; Casado I; Silva JM; Corcuera MT; Alonso MJ
Eur J Histochem; 2003; 47(2):123-8. PubMed ID: 12777207
[TBL] [Abstract][Full Text] [Related]
50. Identification of the G protein-coupled estrogen receptor (GPER) in human prostate: expression site of the estrogen receptor in the benign and neoplastic gland.
Rago V; Romeo F; Giordano F; Ferraro A; Carpino A
Andrology; 2016 Jan; 4(1):121-7. PubMed ID: 26714890
[TBL] [Abstract][Full Text] [Related]
51. Heat shock protein expression independently predicts clinical outcome in prostate cancer.
Cornford PA; Dodson AR; Parsons KF; Desmond AD; Woolfenden A; Fordham M; Neoptolemos JP; Ke Y; Foster CS
Cancer Res; 2000 Dec; 60(24):7099-105. PubMed ID: 11156417
[TBL] [Abstract][Full Text] [Related]
52. The relation of beclin 1 and bcl-2 expressions in high grade prostatic intraepithelial neoplasia and prostate adenocarcinoma: a tissue microarray study.
Baspinar S; Bircan S; Orhan H; Kapucuoglu N; Bozkurt KK
Pathol Res Pract; 2014 Jul; 210(7):412-8. PubMed ID: 24690321
[TBL] [Abstract][Full Text] [Related]
53. Florid basal cell hyperplasia of the prostate: a histological, ultrastructural, and immunohistochemical analysis.
Yang XJ; Tretiakova MS; Sengupta E; Gong C; Jiang Z
Hum Pathol; 2003 May; 34(5):462-70. PubMed ID: 12792920
[TBL] [Abstract][Full Text] [Related]
54. Differentiation pathways and histogenetic aspects of normal and abnormal prostatic growth: a stem cell model.
Bonkhoff H; Remberger K
Prostate; 1996 Feb; 28(2):98-106. PubMed ID: 8604398
[TBL] [Abstract][Full Text] [Related]
55. Comparative analysis of the nuclear proliferative index (Ki-67) in benign prostate, prostatic intraepithelial neoplasia, and prostatic carcinoma.
Tamboli P; Amin MB; Schultz DS; Linden MD; Kubus J
Mod Pathol; 1996 Oct; 9(10):1015-9. PubMed ID: 8902840
[TBL] [Abstract][Full Text] [Related]
56. Cells in various benign and malignant conditions of the human prostate express different antigenic phenotypes.
Turhan OI; Aydin NE; Sariyüce O; Ozkan S
Int Urol Nephrol; 1998; 30(6):731-44. PubMed ID: 10195869
[TBL] [Abstract][Full Text] [Related]
57. Expression analysis of putative stem cell markers in human benign and malignant prostate.
Ugolkov AV; Eisengart LJ; Luan C; Yang XJ
Prostate; 2011 Jan; 71(1):18-25. PubMed ID: 20583131
[TBL] [Abstract][Full Text] [Related]
58. The expression of pluripotency marker Oct 3/4 in prostate cancer and benign prostate hyperplasia.
Monsef N; Soller M; Isaksson M; Abrahamsson PA; Panagopoulos I
Prostate; 2009 Jun; 69(9):909-16. PubMed ID: 19274762
[TBL] [Abstract][Full Text] [Related]
59. Expression of growth hormone receptor in human prostatic carcinoma and hyperplasia.
Kölle S; Sinowatz F; Boie G; Temmim-Baker L; Lincoln D
Int J Oncol; 1999 May; 14(5):911-6. PubMed ID: 10200341
[TBL] [Abstract][Full Text] [Related]
60. [Study of growth fraction on fine needle aspirated prostatic tissue smear using monoclonal antibody Ki-67].
Sai S; Takashi M; Miyake K; Koshikawa T
Hinyokika Kiyo; 1991 Aug; 37(8):881-6. PubMed ID: 1957731
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
